Ivosidenib is FDA-approved as a first-line monotherapy for ND IDH1-AML patients if they are ≥75 years or unfit for intensive chemotherapy, a first-line therapy with the IVO/AZA regimen for ND IDH1-AML patients if they are ≥75 years or unfit for intensive chemotherapy, and as monotherapy for relapsed or refractory IDH1-AML. This evidence concerns the gene IDH1 and acute myeloid leukemia.